<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314687</url>
  </required_header>
  <id_info>
    <org_study_id>CT/CP/02/2020</org_study_id>
    <nct_id>NCT04314687</nct_id>
  </id_info>
  <brief_title>Stem Cell and Conditioned Medium for Cerebral Palsy</brief_title>
  <official_title>Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Prodia Stem Cell Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT. Prodia Stem Cell Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem
      cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with
      standard therapy.

      Hypothesis: UCMSCs + CM therapy resulting in higher improvement in cognitive function, gross
      motor function and chemical factors than UCMSCs and standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2020</start_date>
  <completion_date type="Anticipated">December 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gross Motor Function</measure>
    <time_frame>3 month after stem cells</time_frame>
    <description>Gross Motor Function Classification System (GMFCS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Function</measure>
    <time_frame>6 month after stem cells</time_frame>
    <description>Gross Motor Function Classification System (GMFCS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Function</measure>
    <time_frame>3 month after stem cells</time_frame>
    <description>Gross Motor Function Measure (GMFM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Function</measure>
    <time_frame>6 month after stem cells</time_frame>
    <description>Gross Motor Function Measure (GMFM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>3 month after stem cells</time_frame>
    <description>Bayley Scales of Infant Development (BSID) version III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>6 month after stem cells</time_frame>
    <description>Bayley Scales of Infant Development (BSID) version III</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical Marker</measure>
    <time_frame>3 month after stem cells</time_frame>
    <description>Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical Marker</measure>
    <time_frame>6 month after stem cells</time_frame>
    <description>Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>UCMSCs + CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UCMSCs + CM is administered via intrathecal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UCMSCs is administered via intrathecal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Mesenchymal Stem Cells</intervention_name>
    <description>The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.</description>
    <arm_group_label>UCMSCs</arm_group_label>
    <arm_group_label>UCMSCs + CM</arm_group_label>
    <other_name>Allogeneic Mesenchymal Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conditioned Medium</intervention_name>
    <description>Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.</description>
    <arm_group_label>UCMSCs + CM</arm_group_label>
    <other_name>Umbilical Cord Mesenchymal Stem Cells derived Conditioned Medium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Standard therapy for cerebral palsy such as physiotherapy</description>
    <arm_group_label>Standard Therapy</arm_group_label>
    <other_name>Physiotheraphy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as Cerebral palsy with total body involvement type

          -  Age between 6 month - 3 years old

          -  Parents requesting for cell therapy

          -  The parents give sign in informed consent form do to examination, therapy, blood
             sampling collection and observation for their child

        Exclusion Criteria:

          -  Head circumference less than -3 SD (more than 3 cm) Nellhaus standard

          -  Have diagnosed meningitis and encephalitis

          -  Have diagnosed congenital infection i.e. toxoplasmosis, rubella congenital,
             cytomegalovirus

          -  Have diagnosed metabolic disorder, chromosome disorder, congenital malformation or
             neuroregeneratif disease

          -  Progressive disorder

          -  Regressive development disorder

          -  Severe anatomical abnormalities in Brain MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hardiono D. Pusponegoro</last_name>
    <phone>088293176579</phone>
    <email>hardionodp@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Retna Sartika</last_name>
    <email>c.sartika@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indonesian National Brain Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Mesenchymal Stem Cells</keyword>
  <keyword>Umbilical Cord Mesenchymal Stem Cells</keyword>
  <keyword>Intrathecal Injection</keyword>
  <keyword>Cerebral Palsy</keyword>
  <keyword>Conditioned Medium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

